Home Applications 208325 Application 208325
Type NDA
Sponsor KAI PHARMS INC Application Products# Product, Drug, Ingredient table Product Drug Ingredient Form Strength Reference drug Reference standard 001 PARSABIV ETELCALCETIDE SOLUTION;INTRAVENOUS 2.5MG/0.5ML (2.5MG/0.5ML) Yes Yes 002 PARSABIV ETELCALCETIDE SOLUTION;INTRAVENOUS 5MG/ML (5MG/ML) Yes Yes 003 PARSABIV ETELCALCETIDE SOLUTION;INTRAVENOUS 10MG/2ML (5MG/ML) Yes Yes
Source provenance: Browse the complete Orange Book source catalog · source snapshot 43 .
Orange Book products# Current product rows page 1 of 1 · 3 matching rows.
Application-product, Trade name, Ingredient table Application-product Trade name Ingredient Strength Dosage form / route TE codes RLD / RS Approval date N208325-001 PARSABIV ETELCALCETIDE 2.5MG/0.5ML (2.5MG/0.5ML) SOLUTION / INTRAVENOUS RLD, RS 2017-02-07 N208325-002 PARSABIV ETELCALCETIDE 5MG/ML (5MG/ML) SOLUTION / INTRAVENOUS RLD, RS 2017-02-07 N208325-003 PARSABIV ETELCALCETIDE 10MG/2ML (5MG/ML) SOLUTION / INTRAVENOUS RLD, RS 2017-02-07
Orange Book patents# Current patent rows page 1 of 1 · 24 matching rows.
Application-product, Patent, Expiration table Application-product Patent Expiration Use code Coverage / status Submission date N208325-001 8377880 2030-07-29 Drug substance, Drug product 2017-06-01 N208325-001 9278995 2030-07-29 Drug substance 2017-06-01 N208325-001 9701712 2030-07-29 U-2014 Drug substance, Drug product 2017-07-14 N208325-001 8999932 2031-02-07 U-2014 Drug substance, Drug product 2017-06-01 N208325-001 10344765 2034-06-27 Drug product 2019-07-19 N208325-001 11162500 2034-06-27 Drug product 2021-11-12 N208325-001 11959486 2034-06-27 U-2014 Drug product 2024-05-10 N208325-001 9820938 2034-06-27 Drug product 2017-11-29 N208325-002 8377880 2030-07-29 Drug substance, Drug product 2017-06-01 N208325-002 9278995 2030-07-29 Drug substance 2017-06-01 N208325-002 9701712 2030-07-29 U-2014 Drug substance, Drug product 2017-07-14 N208325-002 8999932 2031-02-07 U-2014 Drug substance, Drug product 2017-06-01 N208325-002 10344765 2034-06-27 Drug product 2019-07-19 N208325-002 11162500 2034-06-27 Drug product 2021-11-12 N208325-002 11959486 2034-06-27 U-2014 Drug product 2024-05-10 N208325-002 9820938 2034-06-27 Drug product 2017-11-29 N208325-003 8377880 2030-07-29 Drug substance, Drug product 2017-06-01 N208325-003 9278995 2030-07-29 Drug substance 2017-06-01 N208325-003 9701712 2030-07-29 U-2014 Drug substance, Drug product 2017-07-14 N208325-003 8999932 2031-02-07 U-2014 Drug substance, Drug product 2017-06-01 N208325-003 10344765 2034-06-27 Drug product 2019-07-19 N208325-003 11162500 2034-06-27 Drug product 2021-11-12 N208325-003 11959486 2034-06-27 U-2014 Drug product 2024-05-10 N208325-003 9820938 2034-06-27 Drug product 2017-11-29
Observed Orange Book product history# Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
Product history page 1 of 4 · 129 observed states.
Captured, Edition, Application-product table Captured Edition Application-product Trade name Strength Dosage form / route Product TE source text RLD / RS Approval date Source SHA-256 2026-09-14 22:38:34 2026-08 N208325-001 PARSABIV 2.5MG/0.5ML (2.5MG/0.5ML) SOLUTION / INTRAVENOUS RLD, RS 2017-02-07 84e616aacf4f…2026-09-14 22:38:34 2026-08 N208325-002 PARSABIV 5MG/ML (5MG/ML) SOLUTION / INTRAVENOUS RLD, RS 2017-02-07 84e616aacf4f…2026-09-14 22:38:34 2026-08 N208325-003 PARSABIV 10MG/2ML (5MG/ML) SOLUTION / INTRAVENOUS RLD, RS 2017-02-07 84e616aacf4f…2026-08-18 06:07:40 2026-07 N208325-001 PARSABIV 2.5MG/0.5ML (2.5MG/0.5ML) SOLUTION / INTRAVENOUS RLD, RS 2017-02-07 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N208325-002 PARSABIV 5MG/ML (5MG/ML) SOLUTION / INTRAVENOUS RLD, RS 2017-02-07 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N208325-003 PARSABIV 10MG/2ML (5MG/ML) SOLUTION / INTRAVENOUS RLD, RS 2017-02-07 caaa826d4ba7…2026-02-19 14:30 UTC 2026-02 N208325-001 PARSABIV 2.5MG/0.5ML (2.5MG/0.5ML) SOLUTION / INTRAVENOUS RLD, RS 2017-02-07 011fe1cb6892…2026-02-19 14:30 UTC 2026-02 N208325-002 PARSABIV 5MG/ML (5MG/ML) SOLUTION / INTRAVENOUS RLD, RS 2017-02-07 011fe1cb6892…2026-02-19 14:30 UTC 2026-02 N208325-003 PARSABIV 10MG/2ML (5MG/ML) SOLUTION / INTRAVENOUS RLD, RS 2017-02-07 011fe1cb6892…2025-12-14 10:44 UTC · 2 captures of this ZIP 2025-12 N208325-001 PARSABIV 2.5MG/0.5ML (2.5MG/0.5ML) SOLUTION / INTRAVENOUS RLD, RS 2017-02-07 31067a03dcf5…2025-12-14 10:44 UTC · 2 captures of this ZIP 2025-12 N208325-002 PARSABIV 5MG/ML (5MG/ML) SOLUTION / INTRAVENOUS RLD, RS 2017-02-07 31067a03dcf5…2025-12-14 10:44 UTC · 2 captures of this ZIP 2025-12 N208325-003 PARSABIV 10MG/2ML (5MG/ML) SOLUTION / INTRAVENOUS RLD, RS 2017-02-07 31067a03dcf5…2025-08-23 18:47 UTC 2025-08 N208325-001 PARSABIV 2.5MG/0.5ML (2.5MG/0.5ML) SOLUTION / INTRAVENOUS RLD, RS 2017-02-07 6a471c1ec25d…2025-08-23 18:47 UTC 2025-08 N208325-002 PARSABIV 5MG/ML (5MG/ML) SOLUTION / INTRAVENOUS RLD, RS 2017-02-07 6a471c1ec25d…2025-08-23 18:47 UTC 2025-08 N208325-003 PARSABIV 10MG/2ML (5MG/ML) SOLUTION / INTRAVENOUS RLD, RS 2017-02-07 6a471c1ec25d…2025-03-22 03:13 UTC · 3 captures of this ZIP 2025-03 N208325-001 PARSABIV 2.5MG/0.5ML (2.5MG/0.5ML) SOLUTION / INTRAVENOUS RLD, RS 2017-02-07 fd3edfee7708…2025-03-22 03:13 UTC · 3 captures of this ZIP 2025-03 N208325-002 PARSABIV 5MG/ML (5MG/ML) SOLUTION / INTRAVENOUS RLD, RS 2017-02-07 fd3edfee7708…2025-03-22 03:13 UTC · 3 captures of this ZIP 2025-03 N208325-003 PARSABIV 10MG/2ML (5MG/ML) SOLUTION / INTRAVENOUS RLD, RS 2017-02-07 fd3edfee7708…2025-02-26 10:13 UTC · 3 captures of this ZIP 2025-02 N208325-001 PARSABIV 2.5MG/0.5ML (2.5MG/0.5ML) SOLUTION / INTRAVENOUS RLD, RS 2017-02-07 b8a1b40f171c…2025-02-26 10:13 UTC · 3 captures of this ZIP 2025-02 N208325-002 PARSABIV 5MG/ML (5MG/ML) SOLUTION / INTRAVENOUS RLD, RS 2017-02-07 b8a1b40f171c…2025-02-26 10:13 UTC · 3 captures of this ZIP 2025-02 N208325-003 PARSABIV 10MG/2ML (5MG/ML) SOLUTION / INTRAVENOUS RLD, RS 2017-02-07 b8a1b40f171c…2025-01-19 17:59 UTC · 7 captures of this ZIP 2025-01 N208325-001 PARSABIV 2.5MG/0.5ML (2.5MG/0.5ML) SOLUTION / INTRAVENOUS RLD, RS 2017-02-07 03ed91905a0d…2025-01-19 17:59 UTC · 7 captures of this ZIP 2025-01 N208325-002 PARSABIV 5MG/ML (5MG/ML) SOLUTION / INTRAVENOUS RLD, RS 2017-02-07 03ed91905a0d…2025-01-19 17:59 UTC · 7 captures of this ZIP 2025-01 N208325-003 PARSABIV 10MG/2ML (5MG/ML) SOLUTION / INTRAVENOUS RLD, RS 2017-02-07 03ed91905a0d…2024-12-13 21:23 UTC · 2 captures of this ZIP 2024-12 N208325-001 PARSABIV 2.5MG/0.5ML (2.5MG/0.5ML) SOLUTION / INTRAVENOUS RLD, RS 2017-02-07 2680178bc6a6…2024-12-13 21:23 UTC · 2 captures of this ZIP 2024-12 N208325-002 PARSABIV 5MG/ML (5MG/ML) SOLUTION / INTRAVENOUS RLD, RS 2017-02-07 2680178bc6a6…2024-12-13 21:23 UTC · 2 captures of this ZIP 2024-12 N208325-003 PARSABIV 10MG/2ML (5MG/ML) SOLUTION / INTRAVENOUS RLD, RS 2017-02-07 2680178bc6a6…2024-09-14 05:58 UTC · 2 captures of this ZIP 2024-09 N208325-001 PARSABIV 2.5MG/0.5ML (2.5MG/0.5ML) SOLUTION / INTRAVENOUS RLD, RS 2017-02-07 5bbf6a4d5a75…2024-09-14 05:58 UTC · 2 captures of this ZIP 2024-09 N208325-002 PARSABIV 5MG/ML (5MG/ML) SOLUTION / INTRAVENOUS RLD, RS 2017-02-07 5bbf6a4d5a75…2024-09-14 05:58 UTC · 2 captures of this ZIP 2024-09 N208325-003 PARSABIV 10MG/2ML (5MG/ML) SOLUTION / INTRAVENOUS RLD, RS 2017-02-07 5bbf6a4d5a75…2024-11-08 22:44 UTC · 3 captures of this ZIP 2024-11 N208325-001 PARSABIV 2.5MG/0.5ML (2.5MG/0.5ML) SOLUTION / INTRAVENOUS RLD, RS 2017-02-07 d8e5a09893c0…2024-11-08 22:44 UTC · 3 captures of this ZIP 2024-11 N208325-002 PARSABIV 5MG/ML (5MG/ML) SOLUTION / INTRAVENOUS RLD, RS 2017-02-07 d8e5a09893c0…2024-11-08 22:44 UTC · 3 captures of this ZIP 2024-11 N208325-003 PARSABIV 10MG/2ML (5MG/ML) SOLUTION / INTRAVENOUS RLD, RS 2017-02-07 d8e5a09893c0…2024-10-29 15:01 UTC 2024-10 N208325-001 PARSABIV 2.5MG/0.5ML (2.5MG/0.5ML) SOLUTION / INTRAVENOUS RLD, RS 2017-02-07 d06236e962d9…2024-10-29 15:01 UTC 2024-10 N208325-002 PARSABIV 5MG/ML (5MG/ML) SOLUTION / INTRAVENOUS RLD, RS 2017-02-07 d06236e962d9…2024-10-29 15:01 UTC 2024-10 N208325-003 PARSABIV 10MG/2ML (5MG/ML) SOLUTION / INTRAVENOUS RLD, RS 2017-02-07 d06236e962d9…2024-08-13 05:28 UTC · 3 captures of this ZIP 2024-08 N208325-001 PARSABIV 2.5MG/0.5ML (2.5MG/0.5ML) SOLUTION / INTRAVENOUS RLD, RS 2017-02-07 79d66fd596c7…2024-08-13 05:28 UTC · 3 captures of this ZIP 2024-08 N208325-002 PARSABIV 5MG/ML (5MG/ML) SOLUTION / INTRAVENOUS RLD, RS 2017-02-07 79d66fd596c7…2024-08-13 05:28 UTC · 3 captures of this ZIP 2024-08 N208325-003 PARSABIV 10MG/2ML (5MG/ML) SOLUTION / INTRAVENOUS RLD, RS 2017-02-07 79d66fd596c7…2024-07-13 05:37 UTC · 2 captures of this ZIP 2024-07 N208325-001 PARSABIV 2.5MG/0.5ML (2.5MG/0.5ML) SOLUTION / INTRAVENOUS RLD, RS 2017-02-07 301d65b070ca…
Observed Orange Book patent history# Patent history page 1 of 24 · 924 observed states.
Captured, Edition, Application-product table Captured Edition Application-product Patent Expiration Use code Coverage / status Submission date Source SHA-256 2026-09-14 22:38:34 2026-08 N208325-001 8377880 2030-07-29 Drug substance, Drug product 2017-06-01 84e616aacf4f…2026-09-14 22:38:34 2026-08 N208325-001 9278995 2030-07-29 Drug substance 2017-06-01 84e616aacf4f…2026-09-14 22:38:34 2026-08 N208325-001 9701712 2030-07-29 U-2014 Drug substance, Drug product 2017-07-14 84e616aacf4f…2026-09-14 22:38:34 2026-08 N208325-001 8999932 2031-02-07 U-2014 Drug substance, Drug product 2017-06-01 84e616aacf4f…2026-09-14 22:38:34 2026-08 N208325-001 10344765 2034-06-27 Drug product 2019-07-19 84e616aacf4f…2026-09-14 22:38:34 2026-08 N208325-001 11162500 2034-06-27 Drug product 2021-11-12 84e616aacf4f…2026-09-14 22:38:34 2026-08 N208325-001 11959486 2034-06-27 U-2014 Drug product 2024-05-10 84e616aacf4f…2026-09-14 22:38:34 2026-08 N208325-001 9820938 2034-06-27 Drug product 2017-11-29 84e616aacf4f…2026-09-14 22:38:34 2026-08 N208325-002 8377880 2030-07-29 Drug substance, Drug product 2017-06-01 84e616aacf4f…2026-09-14 22:38:34 2026-08 N208325-002 9278995 2030-07-29 Drug substance 2017-06-01 84e616aacf4f…2026-09-14 22:38:34 2026-08 N208325-002 9701712 2030-07-29 U-2014 Drug substance, Drug product 2017-07-14 84e616aacf4f…2026-09-14 22:38:34 2026-08 N208325-002 8999932 2031-02-07 U-2014 Drug substance, Drug product 2017-06-01 84e616aacf4f…2026-09-14 22:38:34 2026-08 N208325-002 10344765 2034-06-27 Drug product 2019-07-19 84e616aacf4f…2026-09-14 22:38:34 2026-08 N208325-002 11162500 2034-06-27 Drug product 2021-11-12 84e616aacf4f…2026-09-14 22:38:34 2026-08 N208325-002 11959486 2034-06-27 U-2014 Drug product 2024-05-10 84e616aacf4f…2026-09-14 22:38:34 2026-08 N208325-002 9820938 2034-06-27 Drug product 2017-11-29 84e616aacf4f…2026-09-14 22:38:34 2026-08 N208325-003 8377880 2030-07-29 Drug substance, Drug product 2017-06-01 84e616aacf4f…2026-09-14 22:38:34 2026-08 N208325-003 9278995 2030-07-29 Drug substance 2017-06-01 84e616aacf4f…2026-09-14 22:38:34 2026-08 N208325-003 9701712 2030-07-29 U-2014 Drug substance, Drug product 2017-07-14 84e616aacf4f…2026-09-14 22:38:34 2026-08 N208325-003 8999932 2031-02-07 U-2014 Drug substance, Drug product 2017-06-01 84e616aacf4f…2026-09-14 22:38:34 2026-08 N208325-003 10344765 2034-06-27 Drug product 2019-07-19 84e616aacf4f…2026-09-14 22:38:34 2026-08 N208325-003 11162500 2034-06-27 Drug product 2021-11-12 84e616aacf4f…2026-09-14 22:38:34 2026-08 N208325-003 11959486 2034-06-27 U-2014 Drug product 2024-05-10 84e616aacf4f…2026-09-14 22:38:34 2026-08 N208325-003 9820938 2034-06-27 Drug product 2017-11-29 84e616aacf4f…2026-08-18 06:07:40 2026-07 N208325-001 8377880 2030-07-29 Drug substance, Drug product 2017-06-01 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N208325-001 9278995 2030-07-29 Drug substance 2017-06-01 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N208325-001 9701712 2030-07-29 U-2014 Drug substance, Drug product 2017-07-14 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N208325-001 8999932 2031-02-07 U-2014 Drug substance, Drug product 2017-06-01 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N208325-001 10344765 2034-06-27 Drug product 2019-07-19 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N208325-001 11162500 2034-06-27 Drug product 2021-11-12 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N208325-001 11959486 2034-06-27 U-2014 Drug product 2024-05-10 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N208325-001 9820938 2034-06-27 Drug product 2017-11-29 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N208325-002 8377880 2030-07-29 Drug substance, Drug product 2017-06-01 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N208325-002 9278995 2030-07-29 Drug substance 2017-06-01 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N208325-002 9701712 2030-07-29 U-2014 Drug substance, Drug product 2017-07-14 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N208325-002 8999932 2031-02-07 U-2014 Drug substance, Drug product 2017-06-01 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N208325-002 10344765 2034-06-27 Drug product 2019-07-19 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N208325-002 11162500 2034-06-27 Drug product 2021-11-12 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N208325-002 11959486 2034-06-27 U-2014 Drug product 2024-05-10 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N208325-002 9820938 2034-06-27 Drug product 2017-11-29 caaa826d4ba7…
Observed Orange Book exclusivity history# Exclusivity history page 1 of 2 · 54 observed states.
openFDA label cross-check# OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
Matched openFDA labels page 1 of 1 · 1 matching rows.
Reported adverse events (FAERS/openFDA)# Adverse event summaries are temporarily unavailable. Other product information remains available.
NDC Listings For This Application# NDC listings for this application page 1 of 1 · 15 matching rows.
NDC, Name, Nonproprietary name table NDC Name Nonproprietary name Labeler Marketing category Status 55513-740 PARSABIV etelcalcetide Amgen Inc NDA Current 55513-740 PARSABIV etelcalcetide Amgen Inc NDA Current 55513-740 PARSABIV etelcalcetide Amgen Inc NDA Current 55513-740 PARSABIV etelcalcetide Amgen Inc NDA Current 55513-740 PARSABIV etelcalcetide Amgen Inc NDA Current 55513-741 PARSABIV etelcalcetide Amgen Inc NDA Current 55513-741 PARSABIV etelcalcetide Amgen Inc NDA Current 55513-741 PARSABIV etelcalcetide Amgen Inc NDA Current 55513-741 PARSABIV etelcalcetide Amgen Inc NDA Current 55513-741 PARSABIV etelcalcetide Amgen Inc NDA Current 55513-742 PARSABIV etelcalcetide Amgen Inc NDA Current 55513-742 PARSABIV etelcalcetide Amgen Inc NDA Current 55513-742 PARSABIV etelcalcetide Amgen Inc NDA Current 55513-742 PARSABIV etelcalcetide Amgen Inc NDA Current 55513-742 PARSABIV etelcalcetide Amgen Inc NDA Current
Documents# Document, Submission type, Date table Document Submission type Date 66210 SUPPL 2021-02-16 57962 SUPPL 2019-03-12 57957 SUPPL 2019-03-12 55324 SUPPL 2018-08-27 55255 SUPPL 2018-08-21 47628 ORIG 2017-03-21 47138 ORIG 2017-02-08 47131 ORIG 2017-02-08